Heterocyclic compounds and uses thereof

1. A compound of Formula (I):

or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:

U is O or S;

W is A or AB, wherein A and B are fused together;

A is phenyl or 5- to 6-membered heteroaryl, each of which is optionally substituted with R 17a , wherein A and R 17a together are

and n is 0, 1, 2, 3, or 4;

B is C 3 -C 6 cycloalkyl, 3- to 7-membered heterocyclyl, 5- to 7-membered heteroaryl, or C 6 aryl, each of which is optionally substituted with R 17b , wherein A, B, R 17a , and R 17b together are

and m and n are independently 0, 1, 2, 3, or 4;

X is hydrogen or C 1 -C 6 alkyl;

Y is N or CR 1 ;

Z is N or CR 2 ;

R 1 and R 2 are independently hydrogen or R 17a ;

R 3a and R 3b are independently hydrogen or R 17a , or

R 3a and R 3b are taken together with the carbon to which they are attached to form a C 3 -C 6 cycloalkyl;

each R 17b is independently oxo or R 17a , or

any two R 17b groups, when bound to the same carbon atom or two different carbon atoms, are taken together with the carbon or carbons to which they are attached to form a C 3 -C 6 cycloalkyl or 3- to 7-membered heterocyclyl, each is optionally substituted by R 10 ;

each R 17a is independently C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, halogen, —CN, —OR 10 , —SR 10 , —NR 11 R 12 , —C(O)R 10 , —C(O)OR 10 , —Si(C 1 -C 6 alkyl) 3 , —C(O)NR 11 R 12 , —OC(O)NR 11 R 12 , —NR 10 C(O)R 11 , —NR 10 C(O)NR 11 R 12 , —S(O) 2 R 10 , —NR 10 S(O) 2 R 11 , —S(O) 2 NR 11 R 12 , C 3 -C 6 cycloalkyl, 3- to 12-membered heterocyclyl, 5- to 10-membered heteroaryl, C 6 -C 14 aryl, —(C 1 -C 3 alkylene)CN, —(C 1 -C 3 alkylene)OR 10 , —(C 1 -C 3 alkylene)SR 10 , —(C 1 -C 3 alkylene)NR 11 R 12 , —(C 1 -C 3 alkylene)CF 3 , —(C 1 -C 3 alkylene)C(O)R 10 , —(C 1 -C 3 alkylene)C(O)NR 11 R 12 , —(C 1 -C 3 alkylene)NR 10 C(O)R 1 , —(C 1 -C 3 alkylene)NR 1 C(O)NR 11 R 12 , —(C 1 -C 3 alkylene)S(O) 2 R 10 , —(C 1 -C 3 alkylene)NR 10 S(O) 2 R 11 , —(C 1 -C 3 alkylene)S(O) 2 NR 11 R 12 , —(C 1 -C 3 alkylene)(C 3 -C 6 cycloalkyl), —(C 1 -C 3 alkylene)(3- to 12-membered heterocyclyl), —(C 1 -C 3 alkylene)(5- to 10-membered heteroaryl) or —(C 1 -C 3 alkylene)(C 6 -C 14 aryl), wherein the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, —OR 10 , —SR 10 , —NR 11 R 12 , —C(O)R 10 , —C(O)OR 10 , —Si(C 1 -C 6 alkyl) 3 , —C(O)NR 11 R 12 , —OC(O)NR 11 R 12 , —NR 10 C(O)R 11 , —NR 10 C(O)NR 11 R 12 , —S(O) 2 R 10 , —NR 10 S(O) 2 R 11 , —S(O) 2 NR 11 R 12 , C 3 -C 6 cycloalkyl, 3- to 12-membered heterocyclyl, 5- to 10-membered heteroaryl, C 6 -C 14 aryl, —(C 1 -C 3 alkylene)CN, —(C 1 -C 3 alkylene)OR 10 , —(C 1 -C 3 alkylene)SR 10 , —(C 1 -C 3 alkylene)NR 11 R 12 , —(C 1 -C 3 alkylene)CF 3 , —(C 1 -C 3 alkylene)C(O)R 10 , —(C 1 -C 3 alkylene)C(O)NR 11 R 12 , —(C 1 -C 3 alkylene)NR 10 C(O)R 11 , —(C 1 -C 3 alkylene)NR 1 C(O)NR 11 R 12 , —(C 1 -C 3 alkylene)S(O) 2 R 10 , —(C 1 -C 3 alkylene)NR 10 S(O) 2 R 11 , —(C 1 -C 3 alkylene)S(O) 2 NR 11 R 12 , —(C 1 -C 3 alkylene)(C 3 -C 6 cycloalkyl), —(C 1 -C 3 alkylene)(3- to 12-membered heterocyclyl), —(C 1 -C 3 alkylene)(5- to 10-membered heteroaryl) and —(C 1 -C 3 alkylene)(C 6 -C 14 aryl) of R 17a are each independently optionally substituted by halogen, oxo, —OR 13 , —NR 13 R 14 , —C(O)R 13 , —C(O)NR 13 R 14 , —NR 13 C(O)R 14 , —S(O) 2 R 13 , —NR 13 S(O) 2 R 14 , —S(O) 2 NR 13 R 14 , —(C 1 -C 3 alkylene)C(O)NR 13 R 14 , —(C 1 -C 3 alkylene)NR 13 C(O)R 14 , —(C 1 -C 3 alkylene)S(O) 2 R 13 , —(C 1 -C 3 alkylene)NR 13 S(O) 2 R 14 , —(C 1 -C 3 alkylene)S(O) 2 NR 13 R 14 , —(C 1 -C 3 alkylene)(C 3 -C 6 cycloalkyl), —(C 1 -C 3 alkylene)(3- to 12-membered heterocyclyl), —Si(C 1 -C 6 alkyl) 3 , —CN, —(C 1 -C 3 alkylene)OR 13 , —(C 1 -C 3 alkylene)NR 13 R 14 , —(C 1 -C 3 alkylene)C(O)R 13 , C 3 -C 8 cycloalkyl, or C 1 -C 6 alkyl optionally substituted by oxo, —OH or halogen;

R 4 is hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 12-membered heterocyclyl, 5- to 10-membered heteroaryl, C 6 -C 14 aryl, —(C 1 -C 3 alkylene)(C 3 -C 6 cycloalkyl), —(C 1 -C 3 alkylene)(3- to 12-membered heterocyclyl), —(C 1 -C 3 alkylene)(5- to 10-membered heteroaryl) or —(C 1 -C 3 alkylene)(C 6 -C 14 aryl), wherein the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 12-membered heterocyclyl, 5- to 10-membered heteroaryl, C 6 -C 14 aryl, —(C 1 -C 3 alkylene)(C 3 -C 6 cycloalkyl), —(C 1 -C 3 alkylene)(3- to 12-membered heterocyclyl), —(C 1 -C 3 alkylene)(5- to 10-membered heteroaryl) and —(C 1 -C 3 alkylene)(C 6 -C 14 aryl) of R 4 are each independently optionally substituted by halogen, oxo, —OR 13 , —NR 13 R 14 , —C(O)R 13 , —CN, C 3 -C 8 cycloalkyl, or C 1 -C 6 alkyl optionally substituted by oxo, —OH or halogen;

R 10 is independently hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 14 aryl, 5- to 6-membered heteroaryl or 3- to 6-membered heterocyclyl, wherein the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 14 aryl, 5- to 6-membered heteroaryl and 3- to 6-membered heterocyclyl of R 10 are independently optionally substituted by halogen, oxo, —CN, —OR 15 , —NR s1 R 16 , or C 1 -C 6 alkyl optionally substituted by halogen, —OH or oxo;

R 11 and R 12 are each independently hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 6 -C 14 aryl, 5- to 6-membered heteroaryl or 3- to 6-membered heterocyclyl, wherein the C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 6 -C 14 aryl, 5- to 6-membered heteroaryl and 3- to 6-membered heterocyclyl of R 11 and R 12 are independently optionally substituted by halogen, oxo, —CN, —OR 15 , —NR s1 R 16 or C 1 -C 6 alkyl optionally substituted by halogen, —OH or oxo,

or R 11 and R 12 are taken together with the atom to which they attached to form a 3- to 6-membered heterocyclyl optionally substituted by halogen, oxo, or C 1 -C 6 alkyl optionally substituted by halogen;

R 13 and R 14 are each independently hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, or 3- to 6-membered heterocyclyl, wherein the C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, and 3- to 6-membered heterocyclyl of R 13 and R 14 are optionally substituted by halogen, —CN, —OR 15 , —NR 15 R 16 , or oxo,

or R 13 and R 14 are taken together with the atom to which they attached to form a 3- to 6-membered heterocyclyl optionally substituted by halogen, oxo or C 1 -C 6 alkyl optionally substituted by halogen or oxo; and

R 15 and R 16 are each independently hydrogen, C 1 -C 6 alkyl optionally substituted by halogen or oxo, C 2 -C 6 alkenyl optionally substituted by halogen or oxo, or C 2 -C 6 alkynyl optionally substituted by halogen or oxo,

or R 15 and R 16 are taken together with the atom to which they attached to form a 3- to 6-membered heterocyclyl optionally substituted by halogen, oxo or C 1 -C 6 alkyl optionally substituted by oxo or halogen.

2. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein compound is of Formula (Ia):

or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:

W is A or AB wherein A and B are fused together;

A is phenyl or 6-membered heteroaryl, each of which is optionally substituted with R 17a , wherein A and R 17a together are

and n is 0, 1, 2, 3, or 4;

B is C 3 -C 6 cycloalkyl, 3- to 7-membered heterocyclyl, 5- to 7-membered heteroaryl, or C 6 aryl, each of which is optionally substituted with R 17b , wherein A, B, R 17a , and R 17b together are

and m and n are independently 0, 1, 2, 3, or 4;

X is hydrogen or C 1 -C 6 alkyl;

Y is N or CR 1 ;

Z is N or CR 2 ;

R 1 and R 2 are independently hydrogen or R 17a ;

R 3a and R 3b are independently hydrogen or R 17a , or

R 3a and R 3b are taken together with the carbon to which they are attached to form a C 3 -C 6 cycloalkyl;

each R 17b is independently oxo or R 17a , or

any two R 17b groups, when bound to the same carbon atom, are taken together with the carbon to which they are attached to form a C 3 -C 6 cycloalkyl;

each R 17a is independently C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, halogen, —CN, —OR 10 , —SR 10 , —NR 11 R 12 , —C(O)R 10 , —C(O)NR 11 R 12 , —OC(O)NR 11 R 12 , —NR 10 C(O)R 11 , —NR 10 C(O)NR 11 R 12 , —S(O) 2 R 10 , —NR 10 S(O) 2 R 11 , —S(O) 2 NR 11 R 12 , C 3 -C 6 cycloalkyl, 3- to 12-membered heterocyclyl, 5- to 10-membered heteroaryl, C 6 -C 14 aryl, —(C 1 -C 3 alkylene)CN, —(C 1 -C 3 alkylene)OR 10 , —(C 1 -C 3 alkylene)SR 10 , —(C 1 -C 3 alkylene)NR 11 R 12 , —(C 1 -C 3 alkylene)CF 3 , —(C 1 -C 3 alkylene)C(O)R 10 , —(C 1 -C 3 alkylene)C(O)NR 11 R 12 , —(C 1 -C 3 alkylene)NR 10 C(O)R 11 , —(C 1 -C 3 alkylene)NR 10 C(O)NR 11 R 12 , —(C 1 -C 3 alkylene)S(O) 2 R 10 , —(C 1 -C 3 alkylene)NR 1 S(O) 2 R 11 , —(C 1 -C 3 alkylene)S(O) 2 NR 11 R 12 , —(C 1 -C 3 alkylene)(C 3 -C 6 cycloalkyl), —(C 1 -C 3 alkylene)(3- to 12-membered heterocyclyl), —(C 1 -C 3 alkylene)(5- to 10-membered heteroaryl) or —(C 1 -C 3 alkylene)(C 6 -C 14 aryl), wherein the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, —OR 10 , —SR 10 , —NR 11 R 12 , —C(O)R 10 , —C(O)NR 11 R 12 , —OC(O)NR 11 R 12 , —NR 10 C(O)R 11 , —NR 10 C(O)NR 11 R 12 , —S(O) 2 R 10 , —NR 10 S(O) 2 R 11 , —S(O) 2 NR 11 R 12 , C 3 -C 6 cycloalkyl, 3- to 12-membered heterocyclyl, 5- to 10-membered heteroaryl, C 6 -C 14 aryl, —(C 1 -C 3 alkylene)CN, —(C 1 -C 3 alkylene)OR 10 , —(C 1 -C 3 alkylene)SR 10 , —(C 1 -C 3 alkylene)NR 11 R 12 , —(C 1 -C 3 alkylene)CF 3 , —(C 1 -C 3 alkylene)C(O)R 10 , —(C 1 -C 3 alkylene)C(O)NR 11 R 12 , —(C 1 -C 3 alkylene)NR 10 C(O)R 11 , —(C 1 -C 3 alkylene)NR 1 C(O)NR 11 R 12 , —(C 1 -C 3 alkylene)S(O) 2 R 10 , —(C 1 -C 3 alkylene)NR 10 S(O) 2 R 1 , —(C 1 -C 3 alkylene)S(O) 2 NR 11 R 12 , —(C 1 -C 3 alkylene)(C 3 -C 6 cycloalkyl), —(C 1 -C 3 alkylene)(3- to 12-membered heterocyclyl), —(C 1 -C 3 alkylene)(5- to 10-membered heteroaryl) and —(C 1 -C 3 alkylene)(C 6 -C 14 aryl) of R 17a are each independently optionally substituted by halogen, oxo, —OR 13 , —NR 13 R 14 , —C(O)R 13 , —CN, —(C 1 -C 3 alkylene)OR 13 , —(C 1 -C 3 alkylene)NR 13 R 14 , —(C 1 -C 3 alkylene)C(O)R 13 , C 3 -C 8 cycloalkyl, or C 1 -C 6 alkyl optionally substituted by oxo, —OH or halogen;

R 4 is hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 12-membered heterocyclyl, 5- to 10-membered heteroaryl, C 6 -C 14 aryl, —(C 1 -C 3 alkylene)(C 3 -C 6 cycloalkyl), —(C 1 -C 3 alkylene)(3- to 12-membered heterocyclyl), —(C 1 -C 3 alkylene)(5- to 10-membered heteroaryl) or —(C 1 -C 3 alkylene)(C 6 -C 14 aryl), wherein the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 12-membered heterocyclyl, 5- to 10-membered heteroaryl, C 6 -C 14 aryl, —(C 1 -C 3 alkylene)(C 3 -C 6 cycloalkyl), —(C 1 -C 3 alkylene)(3- to 12-membered heterocyclyl), —(C 1 -C 3 alkylene)(5- to 10-membered heteroaryl) and —(C 1 -C 3 alkylene)(C 6 -C 14 aryl) of R 4 are each independently optionally substituted by halogen, oxo, —OR 13 , —NR 13 R 14 , —C(O)R 13 , —CN, C 3 -C 8 cycloalkyl, or C 1 -C 6 alkyl optionally substituted by oxo, —OH or halogen;

R 10 is independently hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 6 -C 14 aryl, 5- to 6-membered heteroaryl or 3- to 6-membered heterocyclyl, wherein the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 14 aryl, 5- to 6-membered heteroaryl and 3- to 6-membered heterocyclyl of R 10 are independently optionally substituted by halogen, oxo, —CN, —OR 15 , —NR 15 R 16 , or C 1 -C 6 alkyl optionally substituted by halogen, —OH or oxo;

R 11 and R 12 are each independently hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 6 -C 14 aryl, 5- to 6-membered heteroaryl or 3- to 6-membered heterocyclyl, wherein the C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 6 -C 14 aryl, 5- to 6-membered heteroaryl and 3- to 6-membered heterocyclyl of R 11 and R 12 are independently optionally substituted by halogen, oxo, —CN, —OR 15 , —NR s1 R 16 or C 1 -C 6 alkyl optionally substituted by halogen, —OH or oxo,

or R 11 and R 12 are taken together with the atom to which they attached to form a 3- to 6-membered heterocyclyl optionally substituted by halogen, oxo, or C 1 -C 6 alkyl optionally substituted by halogen;

R 13 and R 14 are each independently hydrogen or C 1 -C 6 alkyl, wherein the C 1 -C 6 alkyl of R 13 and R 14 are optionally substituted by halogen, —OR 15 , —NR 15 R 16 , or oxo,

or R 13 and R 14 are taken together with the atom to which they attached to form a 3- to 6-membered heterocyclyl optionally substituted by halogen, oxo or C 1 -C 6 alkyl optionally substituted by halogen or oxo; and

R 15 and R 16 are each independently hydrogen, C 1 -C 6 alkyl optionally substituted by halogen or oxo, C 2 -C 6 alkenyl optionally substituted by halogen or oxo, or C 2 -C 6 alkynyl optionally substituted by halogen or oxo,

or R 15 and R 16 are taken together with the atom to which they attached to form a 3- to 6-membered heterocyclyl optionally substituted by halogen, oxo or C 1 -C 6 alkyl optionally substituted by oxo or halogen.

3. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is of Formula (Ib):

4. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Y is N.

5. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Y is CR 1 .

6. The compound of claim 5 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 1 is hydrogen.

7. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Z is N.

8. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Z is CR 2 .

9. The compound of claim 8 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is hydrogen.

10. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein at least one of Y and Z is N.

11. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is of Formula (IIa):

12. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is of Formula (IIb):

13. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is of Formula (IIIa):

14. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is of Formula (IIIb):

15. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is of Formula (IVa):

16. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is of Formula (IVb):

17. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X is C 1 -C 6 alkyl.

18. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X is methyl.

19. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X is hydrogen.

20. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 3a and R 3b are independently hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, halogen, —CN, —OR 10 , —SR 10 , —NR 11 R 12 , —C(O)R 10 , or —C(O)NR 11 R 12 ; or R 3a and R 3b are taken together with the carbon to which they are attached to form a C 3 -C 6 cycloalkyl.

21. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 3a and R 3b are independently hydrogen or C 1 -C 6 alkyl; or R 3a and R 3b are taken together with the carbon to which they are attached to form a C 3 -C 6 cycloalkyl.

22. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 3a and R 3b are both hydrogen.

23. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 4 is 5- to 10-membered heteroaryl, C 1 -C 6 alkyl, —(C 1 -C 3 alkylene)(C 3 -C 6 cycloalkyl), —(C 1 -C 3 alkylene)(3- to 12-membered heterocyclyl), —(C 1 -C 3 alkylene)(5- to 10-membered heteroaryl), —(C 1 -C 3 alkylene)(C 6 -C 14 aryl), or C 6 -C 14 aryl, each of which is optionally substituted by halogen, —CN, —NR 13 R 14 , —C(O)R 13 , —OR 13 , or C 1 -C 6 alkyl optionally substituted by —OH.

24. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 4 is phenyl optionally substituted by halogen.

25. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 4 is selected from the group consisting of:

methyl, ethyl, isopropyl, cyclopropyl,

26. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:

W is A;

A is phenyl or 6-membered heteroaryl, each of which is optionally substituted with R 17a wherein A and R 17a together are

and n is 0, 1, 2, 3, or 4.

27. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A is phenyl optionally substituted with R 17a .

28. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A is pyridinyl optionally substituted with R 17a .

29. The compound of claim 26 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 17a is independently 3- to 12-membered heterocyclyl, —(C 1 -C 3 alkylene)OR 10 , C 1 -C 6 alkyl optionally substituted by halogen or —OH, —C(O)NR 11 R 12 , —(C 1 -C 3 alkylene)NR 11 R 12 , —CN, halogen, —NR 11 R 12 , C 3 -C 6 cycloalkyl, or —OR 10 , wherein the 3- to 12-membered heterocyclyl of R 17a is optionally substituted with C 1 -C 6 alkyl optionally substituted by halogen or —OH, —C(O)R 13 , —(C 1 -C 3 alkylene)OR 13 , —S(O) 2 R 13 , C 3 -C 8 cycloalkyl, oxo, halogen, or —OR 13 .

30. The compound of claim 26 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 17a is independently C 1 -C 6 alkyl optionally substituted by halogen or —OH, halogen, —CN, or 3- to 12-membered heterocyclyl optionally substituted with C 1 -C 6 alkyl optionally substituted by halogen or —OH.

31. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein W is selected from the group consisting of:

wherein the wavy lines denote attachment points to the parent molecule.

32. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein

W is AB wherein A and B are fused together;

A is phenyl or 6-membered heteroaryl, each of which is optionally substituted with R 17a , wherein A and R 17a together are

and n is 0, 1, 2, 3, or 4;

B is C 3 -C 6 cycloalkyl, 3- to 7-membered heterocyclyl, 5- to 7-membered heteroaryl, or C 6 aryl, each of which is optionally substituted with R 17b , wherein A, B, R 17a , and R 17b together are

and m and n are independently 0, 1, 2, 3, or 4.

33. The compound of claim 32 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A, B, R 17a and R 17b together are

34. The compound of claim 32 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A, B, R 17a and R 17b together are

35. The compound of claim 32 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A, B, R 17a and R 17b together are

36. The compound of claim 32 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A, B, R 17a and R 17b together are

37. The compound of claim 32 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A, B, R 17a and R 17b together are

38. The compound of claim 32 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein B is 3- to 7-membered heterocyclyl or 5- to 7-membered heteroaryl,

each R 17a is independently —(C 1 -C 3 alkylene)OR 10 , C 1 -C 6 alkyl optionally substituted by halogen, —C(O)NR 11 R 12 , —(C 1 -C 3 alkylene)NR 11 R 12 , —CN, halogen, —NR 11 R 12 , C 3 -C 6 cycloalkyl, or —OR 10 ;

each R 17b is independently oxo, —(C 1 -C 3 alkylene)OR 10 , C 1 -C 6 alkyl optionally substituted by halogen, —C(O)NR 11 R 12 , —(C 1 -C 3 alkylene)NR 11 R 12 , —CN, halogen, —NR 11 R 12 , C 3 -C 6 cycloalkyl, or —OR 10 , or

any two groups R 17b , when bound to the same carbon atom, are taken together with the carbon to which they are attached to form a C 3 -C 6 cycloalkyl;

and m and n are independently 0, 1, 2, or 3.

39. The compound of claim 32 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m is 0.

40. The compound of claim 32 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein m is 1.

41. The compound of claim 32 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein n is 0.

42. The compound of claim 32 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein n is 1.

43. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein W is selected from the group consisting of:

wherein the wavy lines denote attachment points to the parent molecule.

44. A compound selected from the group consisting of:

or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

45. The compound of claim 44 , or a pharmaceutically acceptable salt thereof.

46. A pharmaceutical composition comprising a compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier.

47. The compound of claim 45 , or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

48. The compound of claim 47 , or a pharmaceutically acceptable salt thereof, wherein the compound is

49. The compound of claim 47 , or a pharmaceutically acceptable salt thereof, wherein the compound is

50. The compound of claim 47 , or a pharmaceutically acceptable salt thereof, wherein the compound is

51. The compound of claim 47 , or a pharmaceutically acceptable salt thereof, wherein the compound is

52. The compound of claim 47 , or a pharmaceutically acceptable salt thereof, wherein the compound is

53. The compound of claim 47 , or a pharmaceutically acceptable salt thereof, wherein the compound is

54. The compound of claim 47 , or a pharmaceutically acceptable salt thereof, wherein the compound is

55. The compound of claim 47 , or a pharmaceutically acceptable salt thereof, wherein the compound is

56. The compound of claim 47 , or a pharmaceutically acceptable salt thereof, wherein the compound is

57. The compound of claim 47 , or a pharmaceutically acceptable salt thereof, wherein the compound is

58. The compound of claim 47 , or a pharmaceutically acceptable salt thereof, wherein the compound is

59. The compound of claim 47 , or a pharmaceutically acceptable salt thereof, wherein the compound is